{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-070636","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2024-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.459209+00:00","generated_at":"2026-06-01T05:46:17.774053+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"confidence":"high","headline":"FibroGen stockholders approve 2024 Equity Incentive Plan and elect directors","bullets":["Class I directors elected: Thane Wettig (54.9M for), James Schoeneck (53.1M for), Maykin Ho (53.6M for).","2024 Equity Incentive Plan approved: 44.3M for, 10.8M against; plan adds 2.2M new shares plus prior plan reserve.","Advisory vote on executive compensation approved: 53.5M for, 1.75M against.","PricewaterhouseCoopers ratified as independent auditor for 2024: 72.5M for, 0.2M against.","Say-on-pay frequency: every year preferred (54.8M votes)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-070636","json":"https://secwatch.observer/filing/0000950170-24-070636.json","markdown":"https://secwatch.observer/filing/0000950170-24-070636.md","text":"https://secwatch.observer/filing/0000950170-24-070636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017024070636/0000950170-24-070636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017024070636/fgen-20240605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:46:17.774053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}